The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2022-05-29), PTC Therapeutics's share price is $30.35. PTC Therapeutics's Book Value per Share for the quarter that ended in Mar. 2022 was $-1.27. Hence, PTC Therapeutics's PB Ratio of today is .
The historical rank and industry rank for PTC Therapeutics's PB Ratio or its related term are showing as below:
During the past 11 years, PTC Therapeutics's highest PB Ratio was 2187.50. The lowest was 0.00. And the median was 5.04.
During the past 12 months, PTC Therapeutics's average Book Value Per Share Growth Rate was -130.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -85.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -49.20% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of PTC Therapeutics was 40.00% per year. The lowest was -85.80% per year. And the median was -6.95% per year.
Back to Basics: PB Ratio
PTC Therapeutics PB Ratio Historical Data
The historical data trend for PTC Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
PB Ratio
4.44
4.95
5.01
8.83
1,991.50
PTC Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
PB Ratio
11.39
15.17
25.06
1,991.50
-
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics PB Ratio Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's PB Ratio falls into.
PTC Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
PTC Therapeutics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PTC Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of PTC Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.27(0.88%) Volume: 640,351 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
